Company offices and labs are located in
facilities operated by the National
Research Council of Canada
Corporate Communications
Capital Street Group
TOLL Free : 1-888-684-1183
Direct: (604) 988-8186
info@capitalstreetgroup.com
To receive PharmaGap Inc. press releases by email please send us an electronic request :
Signalling a New Era in Disease Therapy
Anchored by alliances with key partners in the U.S. and Europe, PharmaGap is developing proprietary drug technology that offers the promise of novel new disease therapies, bringing value to both patients and our shareholders.
05.07.2009
PharmaGap Provides Guidance on the Timing of Testing of its lead drug at the National Cancer Institute. Initial data expected by approximately July 17, 2009.
PharmaGap Inc. TSX:GAP.V; OTC:PHRGF.PK is a biopharma company developing proprietary drug compounds targeting a cellular protein family called Protein Kinase C (“PKC”). Scientists and medical researchers from around the world have demonstrated the strong link between the PKC family of enzymes and many serious disease, including cancer, diabetes and inflammatory diseases like arthritis. PharmaGap’s drug compounds are designed to inhibit abnormal activity of PKC found in human disease conditions.
Today, cancer treatment has expanded into a new domain of treatment called targeted therapy. Unlike standard treatment by chemotherapy (highly toxic drugs with extreme patient side effects), targeted drug therapies hold the promise of a more finely tuned treatment regimen that targets only a selected genetic or protein defect within a cancer cell. Targeted therapies, when used in combination with conventional therapies may increase the efficacy of chemotherapy, resulting in lower doses and hence, lowered patient side effects. PhG-alpha-1 is a targeted cancer therapy – it targets PKC in cancer cells – and PharmaGap researchers believe that this novel strategy may significantly improve cancer patient outcomes, along with reducing the unpleasant side effects patients experience using conventional chemotherapy.
PharmaGap’s lead drug (called PhG-alpha-1) is a preclinical-stage molecule being developed as a therapeutic for cancer. In animal testing conducted during 2008 at the National Research Council in Ottawa, Canada’s pre-eminent biological research organization, PhG-alpha-1 demonstrated compelling effects against hard to treat breast and colon cancer, both as single agent therapy, and in combination with conventional chemotherapy (60% decrease in tumour volume in breast cancer study compared to chemotherapy alone).
More recently, PhG-alpha-1 has been accepted for testing at the U.S. government’s prestigious National Cancer Institute near Washington D.C. Additional testing programs are in place at Memorial Sloan-Kettering Cancer Center in New York City, Queen’s University and the University of Ottawa / OHRI.
June 19, 2009 - (AXcess News) Houston - President Obama could learn a thing or two on government spending on healthcare by looking at a Canadian program making investments in early stage companies.
Just ask PharmaGap (TSX: GAP.V ; OTC: PHRGF.PK), one of five companies Canada's National Research Council (NRC) holds an equity stake in.
PharmaGap's competitive advantage is their proprietary drug architecture platform employing sophisticated super-computer molecular modeling. By developing new (or pipeline) drugs using their proven structural molecular design template (patents pending), additional novel drugs are being developed for use in a wide range of human diseases. In March 2009 the Company announced a co-development agreement with Swiss-based MD Biosciences GmbH for a pipeline drug for potential use in arthritis and multiple sclerosis.Other pipeline projects are in progress.
Building Shareholder Value
The Company is pursuing a business strategy to out-license its drug compounds at the late preclinical stage to larger pharmaceutical and life sciences companies. Management believes value is created for PharmaGap shareholders from partnering its compounds with experienced, global pharmaceutical companies who are seeking novel, early-stage drug compounds for their own development pipeline. In this way, the Company’s shareholders benefit from a series of licensing transactions and the risk of any one drug project is distributed among multiple partners.
Teradata Magazine predicted (2007) US $40 billion in sales could be lost at the top 10 pharmaceutical companies as a result of slowdown in R&D innovation and the expiry of patents on major products (with 19 blockbuster drugs losing patents). For this reason the large pharmaceutical companies are eager to partner with smaller firms and seek early stage compounds that they can partner with, or license to bring to clinical development. PharmaGap’s business strategy is aligned to this changing dynamic.
PharmaGap is developing a portfolio of drug compounds targeting PKC. Proprietary computer models of the PKC family are the engine of the Company’s development process and our protected trade secrets.
The ability to rapidly and efficiently design peptide drugs to preferentially target the members of the PKC family is PharmaGap’s competitive advantage.
PharmaGap Drug Pipeline
Executive management and direction of the Company is provided by SC Stormont Corporation, an Ottawa-based strategic advisory firm. Stormont’s Robert McInnis, President and CEO, and Roderick Bryden, Chairman, are experienced tech entrepreneurs formerly with a TSX/Nasdaq listed life science company based in Ottawa.
The senior team is rounded out by Simon Goulet, COO and Gerald Leahy, CFO, both seasoned professionals experienced in finance, business development and licensing, and Dr. Jenny Phipps, Chief Scientific Officer. Stormont, senior management and board members are significant shareholders in the Company.
Share Information
Share Ownership
Exchanges: TSX-Venture / OTCBB
Tickers: GAP / PHRGF
52 week Range ($C): $0.05 -$26.5
Average Daily Volume 543,000
Shares Outstanding 86.2 million
SC Stormont 39%
Founders and Management 10%
Public 48%
Government of Canada 3%
Invest today when you have the strongest potential to make the most stunning profits.
The Above Profiled Company PharmaGap TSX: GAP.V ; OTC: PHRGF.PK Show The Awesome Earning Potential of Little Known Companies That Explode Onto Investor's Radar Screens;
Many of You Are Already Familiar with This.
Is PharmaGap TSX: GAP.V ; OTC: PHRGF.PK Poised and Positioned to Do that For You?
Then You May Feel the Time Has Come to Act...
Look At PharmaGap Today! AMAZING Return Potential!
"Excellent Value - HUGE upside - great trading opportunity too"
To receive PharmaGap press releases by email please send us an electronic request :
Aggressive Investors Should Be On High Alert!
This could be an exciting time to participate in the growth of PharmaGap Inc. The company is expecting soon test results from the US National Cancer Insitute from their lead cancer drug PhG-alpha-1, if the test results are as compelling as previous results of 2008 (80% effectiveness) ..... it could be a windfall!
PharmaGap Inc. TSX: GAP.V ; OTC: PHRGF.PK could become a 2009/2010 major momentum play! There are thousands of eyes on this stock right now and the upside potential is astronomical!
Safe Harbor. The Materials at this Site may contain various forward-looking statements and which may be based on or include assumptions, concerning the Featured Company's operations, future results and prospects.
These forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions of the United States' Private Securities Litigation Reform Act of 1995, TheWallStWhisper.com provides the following cautionary statement identifying important economic, political and technology factors which, among others, could cause the actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.
Such factors include the following:
(1) changes in the current and future business environment, including interest rates and capital and consumer spending;
(2) competitive factors and competitor responses to PharmaGap Inc. (TSX: GAP.V ; OTC: PHRGF.PK ) initiatives;
(3) successful development and market introductions of anticipated products;
(4) changes in government laws and regulations, including taxes;
(5) unstable governments and business conditions in emerging economies;
(6) continuation of the favorable environment to make acquisitions, domestic and foreign, including regulatory requirements and market values of candidates
BREAKING NEWS!
June 19, 2009 - (AXcess News) Houston
PharmaGap, which is developing a cancer targeted therapy drug, PhG-alpha-1, had conducted early tests on mice in 2008 that showed an 80% effective rate in combating breast and colon cancer.
The Ottawa-based pharmaceutical company announced in early May that the U.S.National Cancer Instituted would begin testing PhG-alpha-1 in Bethesda, MD in the NCI's humancell line cancer screen.
Management Team
Robert C. McInnis, President & Chief Executive Officer
Bob joined PharmaGap in December 2004. Prior to this, Bob was the Director of Financial Programs at World Heart Corporation, dealing with various financial structuring programs including responsibility for U.S. and Canadian capital markets regulatory affairs. Previously, Bob was president of SC Stormont Corporation and was involved in the corporate financial management for the Ottawa Senators Hockey Club and The Corel Centre. Before that, Bob was employed at SHL Systemhouse Inc., at the time, Canada’s largest computer system integration company where he held a number of key financial management roles including corporate structuring, and mergers and acquisitions activity. Bob is a chartered accountant and holds a Bachelor of Mathematics degree from the University of Waterloo.
Simon Goulet, Executive Vice President & Chief Operating Officer
Simon joined PharmaGap in December 2003 as Chief Financial Officer and was appointed to his new position in December 2004. Previously, he was Vice President, Investment Banking with Credit Suisse First Boston in New York and TD Securities in New York and Toronto, where he was responsible for numerous assignments raising capital and executing M&A transactions. He is also a co-founder of a company in Greenwich, Connecticut licencing financial software and he has sold medical products to hospitals and clinics for Kodak Canada Inc. Simon has a B.Sc. (Biochemistry) from Queen’s University and an MBA from the University of Western Ontario.
David Barnes, M.D., Clinical Development & Regulatory Affairs Consultant
David has been working with PharmaGap since January 2004 and is responsible for all aspects of the Company’s clinical testing efforts and regulatory affairs. He is the co-founder and Managing Partner of BioTheragene Clinical Research Consultants and the Chalmers Research Group, both well regarded clinical study consultancies based in Ottawa. Previously David was Head of the Biotechnology Drug Evaluation Unit at Health Canada and he was a practicing family physician. David has 10 years experience in molecular biology and clinical research and is former Investigator at the University of Ottawa’s Evidence Based Practice Center. He has been a contract drug development executive for pharmaceutical companies since 2001. David is an M.D., Memorial University of Newfoundland.
Jenny Phipps, Ph.D., Chief Scientific Officer, Director
Co-founder of PharmaGap.
Jenny is an experienced molecular biologist with a strong interest in signal transduction processes and their effect on disease. As CSO, Jenny designed and implemented the core drug development program targeting PKC. Before joining the Company full-time in 2001, Jenny was a senior researcher at the National Research Council of Canada in Ottawa, an adjunct professor at the University of Ottawa (School of Medicine) and an assistant professor of biology at Carleton University (Ottawa). She has a Doctorate (Molecular Genetics) from the Universite Paul Sabatier (France).
Gerald Leahy, Chief Financial Officer
Gerald joined Pharmagap as Chief Financial Officer in December, 2004 bringing more than 20 years of industry experience in public and private companies, including 14 years in the high-tech sector. As a financial professional he has successfully developed and managed finance groups throughout the building and growth stages of companies. He has been involved in private and public financings, international expansion into foreign markets as well as reorganizations. Gerald was a key player in Simware Inc.’s Nasdaq IPO and the eventual merger with Netmanage Inc., and also recently acted as CFO during Linmor Inc.’s strategic sale to Nuvo Network Management Inc. Gerald is a CMA and holds a Bachelor of Commerce degree from Carleton University.
Need A Penny Stock Friendly Broker?
Not all brokerages, online and/or offline, are penny stock friendly.
The brokerages below ARE penny stock friendly. You can trade penny and low priced stocks at these brokerages. They have low or no minimums to set up your account and most importantly, flat or very low trading fees.
Would 1.5 Million "New Investor Eye's" on your Company help?
HotPennyStocksPicks.com is an advertising and information dissemination subsidiary of Direct MediaSolution.com. Which is a property of Shea Enterprises. If you are a publicly traded company and would like to know how you can be profiled on multiple high traffic investor oriented websites
To receive FREE email alerts on stocks undergoing HUGE High Impact Investor Awareness Campaigns BEFORE the big moves occur.
Please enter your email address below and The Wall St. Whisper will alert you on the next big campaigns!
Free Alerts To Soaring Stocks
2006 © thewallstwhisper.com all rights reserved
All brand names and product names used on this website are trade names, service marks, trademarks, or registered trademarks of their respective owners. Furthermore, no mentioned product or brand endorses this website.
